Protagonist Therapeutics (PTGX) News Today → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free PTGX Stock Alerts $25.70 -1.15 (-4.28%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAsif Ali Sells 1,234 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stockamericanbankingnews.com - April 21 at 6:24 AMProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,234 Sharesinsidertrades.com - April 20 at 7:28 AMInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells 1,234 Shares of Stockmarketbeat.com - April 20 at 12:23 AMReadystate Asset Management LP Has $1.31 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - April 18 at 9:37 PMProtagonist Therapeutics (NASDAQ:PTGX) Stock Price Passes Below 50-Day Moving Average of $28.56americanbankingnews.com - April 18 at 4:26 AMVanguard Group Inc. Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - April 9 at 4:08 AMInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 25,000 Shares of Stockinsidertrades.com - April 3 at 4:58 AMProtagonist Therapeutics Inc CEO Sells 25,000 Sharesfinance.yahoo.com - April 3 at 3:29 AMShareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%finance.yahoo.com - April 1 at 4:10 PMProtagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic Partnershipsmarkets.businessinsider.com - March 27 at 11:05 AMProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takedafinanznachrichten.de - March 18 at 9:09 AMWalleye Capital LLC Grows Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - March 18 at 4:17 AMPTGX Apr 2024 15.000 callfinance.yahoo.com - March 15 at 11:37 PMPTGX Apr 2024 30.000 putfinance.yahoo.com - March 15 at 11:37 PMThe People's Market owner snaps up former Protagonist space in heart of NoDa for barbizjournals.com - March 12 at 4:15 PMBuy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113markets.businessinsider.com - March 12 at 12:49 AMStrong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial Outlookmarkets.businessinsider.com - March 11 at 8:33 AMAdage Capital Partners GP L.L.C. Has $11.68 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - March 9 at 6:35 AMProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Kennedy Capital Management LLCmarketbeat.com - March 8 at 7:44 AMSchonfeld Strategic Advisors LLC Purchases New Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - March 7 at 6:41 AMThis Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Yearfinance.yahoo.com - March 3 at 10:14 AMEarnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their Estimatesfinance.yahoo.com - March 2 at 8:20 AMProtagonist Therapeutics Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 1 at 10:46 AM683 Capital Management LLC Sells 81,216 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - March 1 at 10:35 AMProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Forecasted to Post FY2024 Earnings of $2.35 Per Sharemarketbeat.com - March 1 at 8:03 AMWe're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burnfinance.yahoo.com - February 29 at 8:01 AMConnor Clark & Lunn Investment Management Ltd. Sells 23,931 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - February 29 at 6:48 AMBuy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic Partnershipsmarkets.businessinsider.com - February 28 at 6:11 PMAnalysts Are Bullish on These Healthcare Stocks: Gritstone Oncology (GRTS), Protagonist Therapeutics (PTGX)markets.businessinsider.com - February 28 at 1:10 PMProtagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High on Earnings Beatmarketbeat.com - February 28 at 11:27 AMProtagonist Therapeutics (NASDAQ:PTGX) Releases Earnings Results, Beats Estimates By $0.39 EPSmarketbeat.com - February 28 at 10:43 AMProtagonist Therapeutics (NASDAQ:PTGX) PT Raised to $37.00 at JPMorgan Chase & Co.marketbeat.com - February 28 at 10:30 AMProtagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwrightmarketbeat.com - February 28 at 8:30 AMAlgert Global LLC Purchases 45,600 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - February 28 at 6:37 AMHealthcare of Ontario Pension Plan Trust Fund Makes New $1.47 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - February 26 at 6:57 AMProtagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promiseseekingalpha.com - February 25 at 12:45 PMCitigroup Inc. Grows Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - February 23 at 5:14 AMNew England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Verafinance.yahoo.com - February 21 at 6:24 PMProtagonist Therapeutics Reports Granting of Inducement Awardsfinance.yahoo.com - February 20 at 8:59 PMRafferty Asset Management LLC Purchases 64,822 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - February 19 at 7:23 AMPTGX Mar 2024 25.000 callfinance.yahoo.com - February 17 at 12:51 PMSteven Cohen Adjusts Position in Protagonist Therapeutics Incfinance.yahoo.com - February 15 at 7:47 AMCampbell & CO Investment Adviser LLC Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - February 10 at 7:41 AMJump Financial LLC Acquires 21,070 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - February 9 at 5:10 AMProtagonist Pictures Ups Janina Vilsmaier, Mounia Wissinger, Strengthens Sales and Marketing Divisionsmsn.com - February 8 at 8:12 AMProtagonist Pictures Promotes Janina Vilsmaier & Mounia Wissinger; Bolsters Sales & Marketing Teams Ahead Of EFMmsn.com - February 8 at 8:12 AMNew England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Studyfinance.yahoo.com - February 7 at 8:47 PMProtagonist Therapeutics, Inc. to Post FY2023 Earnings of ($2.59) Per Share, Capital One Financial Forecasts (NASDAQ:PTGX)marketbeat.com - February 5 at 1:26 AMProtagonist Therapeutics (NASDAQ:PTGX) Shares Down 6.2% marketbeat.com - February 2 at 1:37 PMProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Forecasted to Earn FY2028 Earnings of ($0.95) Per Sharemarketbeat.com - February 2 at 8:59 AM Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now PTGX Media Mentions By Week PTGX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼0.720.44▲Average Medical News Sentiment PTGX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼53▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Dynavax Technologies News Taro Pharmaceutical Industries News Zai Lab News Harmony Biosciences News Avadel Pharmaceuticals News Supernus Pharmaceuticals News Ardelyx News Amneal Pharmaceuticals News Edgewise Therapeutics News Day One Biopharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
